Source: Exro Technologies
  • Exro Technologies (EXRO) has announced an upsized bought-deal public offering of units for gross proceeds of $17,500,800
  • A syndicate of underwriters have agreed to purchase 10,938,000 units at a price of $1.60 per unit
  • If the over-allotment option is exercised in full, aggregate gross ‎proceeds of the offering will be $20,125,920
  • The offering is scheduled to close on or about February 4, 2022
  • Exro Technologies is a clean technology company
  • Exro Technologies Inc. (EXRO) opened trading at C$1.93 per share

Exro Technologies (EXRO) has announced an upsized bought-deal public offering of units for aggregate gross proceeds of $17,500,800.

A group of underwriters led by Eight Capital and Raymond James Ltd., as lead underwriters and joint bookrunners have agreed to purchase, on a bought deal basis, 10,938,000 units at a price of $1.60 per unit. Each unit consists of one common share and one half of one common share purchase warrant. Each warrant is exercisable into one common share at an exercise price of $2.00 for a period of 36 months from the closing of the offering.

In addition, Exro has granted the underwriters an over-allotment to purchase up to an additional ‎1,640,700 units. In the event the over-allotment option is exercised in full, the aggregate gross ‎proceeds of the offering will be $20,125,920. ‎

The offering is scheduled to close on or about February 4, 2022.

Net proceeds will be used for working capital and general corporate purposes.

Exro Technologies is a clean technology company pioneering intelligent control solutions in power electronics to help solve the most challenging problems in electrification.

Exro Technologies Inc. (EXRO) opened trading at C$1.93 per share.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.